Quarterly Updates5 Jan 2026, 08:58 am
Metropolis Healthcare Ltd Reports 26% Y-o-Y Revenue Growth in Q3FY26
AI Summary
Metropolis Healthcare Ltd has reported a 26% year-on-year consolidated revenue growth in Q3FY26, driven by sustained momentum in preventive and wellness health check-ups under TruHealth and a strong increase in specialty testing volumes across both B2C and B2B channels. The integration of all acquisitions is progressing well, with synergies delivering operational efficiencies and strengthening operating leverage. The TruHealth Wellness and Specialty segments recorded Y-o-Y growth of ~35% and ~33%, respectively. The standalone revenues grew by approx. 15% Y-o-Y, largely on account of increased patient and test volumes and a favorable shift in product mix and realizations.
Key Highlights
- 26% Y-o-Y consolidated revenue growth including revenues from Core Diagnostics, Scientific Pathology, Agra, Dr. Ahuja’s Pathology & Imaging Center, Dehradun and Dr. RS Patil’s Ambika Pathology Laboratory, Kolhapur.
- Integration of acquisitions progressing well with operational efficiencies and strengthening operating leverage.
- TruHealth Wellness and Specialty segments recorded Y-o-Y growth of ~35% and ~33%, respectively.
- Standalone revenues grew by approx. 15% Y-o-Y, largely on account of increased patient and test volumes and a favorable shift in product mix and realizations.
- EBITDA margins for the quarter recorded year-on-year expansion, despite Q3 being a seasonally weaker period for the diagnostic industry.